News
Market and company headlines
ALMSAll
Loading
00:00-05:00Oct 92 Stories
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral therapy for moderate-to-severe plaque psoriasis – Patients switching from placebo or apremilast achieved rapid responses, comparable to those on continuous treatment at Week 48 – On track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026 SOUTH SAN FRANCISCO, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (
Alumis New Phase 3 ONWARD Data Show Envudeucitinib Improved Scalp, Itch And Quality Of Life In Psoriasis, Building On 54% PASI 100 At Week 48; NDA On Track For 4Q 2026
– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral therapy for moderate-to-severe plaque psoriasis– Patients switching
08:00Oct 81 Story
06:00Sep 141 Story
21:00Sep 81 Story
05:00Sep 31 Story
06:00-09:00Sep 24 Stories
Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $37
Oppenheimer analyst Jeff Jones maintains Alumis (NASDAQ:ALMS) with a Outperform and lowers the price target from $55 to $37.
Wells Fargo Maintains Overweight on Alumis, Lowers Price Target to $25
Wells Fargo analyst Derek Archila maintains Alumis (NASDAQ:ALMS) with a Overweight and lowers the price target from $51 to $25.
03:00-05:00Sep 22 Stories
Morgan Stanley Maintains Overweight on Alumis, Lowers Price Target to $29
Morgan Stanley analyst Terence Flynn maintains Alumis (NASDAQ:ALMS) with a Overweight and lowers the price target from $39 to $29.
HC Wainwright & Co. Upgrades Alumis to Buy, Lowers Price Target to $15
HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Alumis (NASDAQ:ALMS) from Neutral to Buy and lowers the price target from $25 to $15.
15:00Sep 11 Story
09:00Aug 141 Story
12:00-17:00Aug 132 Stories
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO – – Alumis remains on track to submit its New Drug Application to FDA for envudeucitinib in moderate-to-severe plaque psoriasis (PsO) in Q4 2026 – – Potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in SLE anticipated in Q3 2026 – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma
Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate
Alumis (NASDAQ:ALMS) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.71) by 56.34 percent. This is a 12.6 percent increase over losses of $(1.27) per share from the same
05:00-10:00Aug 112 Stories
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates
Alumis releases long-term data for psoriasis drug envudeucitinib, boasting top skin clearance rates ahead of a Q4 FDA filing with FDA.
12:00-17:00Aug 102 Stories
Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
– ONWARD3 data show 54% of patients reached complete skin clearance (PASI 100) after 48 weeks of continuous envudeucitinib treatment – – Favorable long-term safety and tolerability profile remained consistent with previously reported data – – On track to submit a New Drug Application to FDA in 4Q 2026 – SOUTH SAN FRANCISCO, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with i
Alumis Reports Topline Results From Ongoing ONWARD3 Long-Term Extension Study Showing 54% Of Patients Reached Complete Skin Clearance After 48 Weeks Of Continuous Envudeucitinib Treatment
– Favorable long-term safety and tolerability profile remained consistent with previously reported data –– On track to submit a New Drug Application to FDA in 4Q 2026 –SOUTH SAN FRANCISCO, Calif., Aug. 10, 2026 (GLOBE
